A Randomized, Double-blind, Multicenter Study to Establish the Safety and Efficacy of Ceftobiprole Medocaril Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections

Trial Profile

A Randomized, Double-blind, Multicenter Study to Establish the Safety and Efficacy of Ceftobiprole Medocaril Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Ceftobiprole (Primary) ; Aztreonam; Vancomycin
  • Indications Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Basilea Pharmaceutica
  • Most Recent Events

    • 23 Feb 2017 New trial record
    • 20 Feb 2017 This trial is expected to begin in mid-2017, according to a Basilea Pharmaceutica media release.
    • 20 Feb 2017 According to a Basilea Pharmaceutica media release, this trial will be conducted under a Special Protocol Assessment and results from this trial may support a potential regulatory filing in the US for the approval of ceftobiprole. This trial is one of the 2 studies in the phase III program of ceftobiprole.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top